Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro.
Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in tumour cell signalling, angiogenesis and apoptosis.
Sorafenib inhibited tumour growth of human hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid carcinoma and several other human tumour xenografts in immunocompromised mice.1
NEXAVAR® 200 film-coated tablets are indicated for the;
- Treatment of patients with advanced renal cell carcinoma (RCC).
- Treatment of patients with advanced inoperable hepatocellular carcinoma (HCC)
- Treatment of patients with locally advanced or metastatic differentiated (papillary and follicular-Hürthle cell) thyroid carcinoma refractory to radioactive iodine.